<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Aurgalys &#187; News</title>
	<atom:link href="http://www.aurgalys.com/category/news/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.aurgalys.com</link>
	<description>Entrepreneurs Serving Entrepreneurs</description>
	<lastBuildDate>Wed, 28 Jul 2010 16:40:06 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>July 26, 2010: Aurgalys &amp; CLS issue a new BioAlliance analyst note : Acyclovir Lauriad® to be registered in EU &#8211; Record turnover for S1 2010</title>
		<link>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/</link>
		<comments>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/#comments</comments>
		<pubDate>Wed, 28 Jul 2010 15:16:36 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1189</guid>
		<description><![CDATA[Aurgalys issued today July26th, 2010, an new analyst report on BioAlliance.

Acyclovir Lauriad®: the Company has engaged discussion with European regulatory agencies and obtained a registration slot
S1 2010 record turnover: €21.3 M versus €4.1 M for the same period in 2009

Since our coverage initiated on June 19th, 2009, the stock increased 61% from €3.44 to €5.53 [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>June 22, 2010: Aurgalys welcomes new partner and opens offices in Argentina</title>
		<link>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/</link>
		<comments>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/#comments</comments>
		<pubDate>Tue, 22 Jun 2010 08:24:41 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1158</guid>
		<description><![CDATA[Paris, Tel-Aviv, Lausanne, Buenos Aires, June 22, 2010 – Aurgalys, a global provider for life sciences companies through corporate finance, business development and interim management services, is pleased to announce today the appointment of Dr Lila Drittanti as Aurgalys partner and the opening of Latin America offices.
Download our press release here ( english)
Télécharger notre communiqué [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>April 7, 2010: Aurgalys-CLS reitarates BUY recommendation on BioAlliance stock [EuroNext: BIO.FP]</title>
		<link>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/</link>
		<comments>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/#comments</comments>
		<pubDate>Wed, 07 Apr 2010 16:30:04 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1122</guid>
		<description><![CDATA[Aurgalys issued today April 7th, 2010, an new analyst report on BioAlliance.
Since our coverage initiated on June 19th, 2009, the stock increased 69% from €3.44 to €5.81 today.
Given the recent Company newsflow with the approval of Setofilm in Europe, the approval of Loramyc in 13 new European countries, making it 26, the new partner Therabel [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jan 22, 2010: Aurgalys-CLS issues new BioAlliance analyst note [EuroNext: BIO.FP] on a very promising 2010 outlook</title>
		<link>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/</link>
		<comments>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/#comments</comments>
		<pubDate>Fri, 22 Jan 2010 17:07:08 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1033</guid>
		<description><![CDATA[Through our analysis we considered that for BioAlliance:

Major milestones were met in 2009
Two products are due to be launched in new markets
Five products currently in clinical development including one which has completed phase III

We recommand a BUY for the stocks with a target price of €12 within one year
Download our BioAlliance Coverage here (available in [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dec 15, 2009: Aurgalys &#8211; CLS has successfully advised Swiss company Evolva  in a CHF21M financial round</title>
		<link>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/</link>
		<comments>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/#comments</comments>
		<pubDate>Tue, 15 Dec 2009 16:21:50 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1055</guid>
		<description><![CDATA[ December 15th, 2009,  Aurgalys and Cukierman &#38; Co Life Sciences Cukierman &#38; Co. Life Sciences annouces that they have successfully advised Swiss company Evolva [SIX: EVE] in a CHF21M financial round
Download our  English Press Release here
]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>August 31, 2009: Aurgalys-CLS publishes new analyst report on BioAlliance [EuroNext: BIO] on promising Acyclovir Lauriad data and company perpectives</title>
		<link>http://www.aurgalys.com/2009/08/august-31-2009-aurgalys-cls-publishes-new-analyst-report-on-bioalliance-euronext-bio-promising-acyclovir-lauriad-raising-loramyc-sales-and-perpectives/</link>
		<comments>http://www.aurgalys.com/2009/08/august-31-2009-aurgalys-cls-publishes-new-analyst-report-on-bioalliance-euronext-bio-promising-acyclovir-lauriad-raising-loramyc-sales-and-perpectives/#comments</comments>
		<pubDate>Mon, 31 Aug 2009 17:06:16 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1031</guid>
		<description><![CDATA[Considering the following key points:
Acyclovir Lauriad® positive phase III results
Loramyc® sales increase for first half 2009
We observe that shares remain undervalued,  thus we reiterate a BUY
recommendation
Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com
]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/08/august-31-2009-aurgalys-cls-publishes-new-analyst-report-on-bioalliance-euronext-bio-promising-acyclovir-lauriad-raising-loramyc-sales-and-perpectives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>June 19, 2009: Aurgalys-CLS initiates analyst coverage of BioAlliance Pharma</title>
		<link>http://www.aurgalys.com/2009/06/june-19-2009-aurgalys-cls-initiates-analyst-coverage-of-bioalliance-pharma/</link>
		<comments>http://www.aurgalys.com/2009/06/june-19-2009-aurgalys-cls-initiates-analyst-coverage-of-bioalliance-pharma/#comments</comments>
		<pubDate>Fri, 19 Jun 2009 11:33:49 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1016</guid>
		<description><![CDATA[
June 19th, 2009: Aurgalys &#8211; CLS  initiates analyst coverage of BioAlliance Pharma [Euronext: BIO]
BioAlliance Pharma is a biopharmaceutical company which develops and markets innovative therapeutics addressing unmet medical needs in the treatment and supportive care of life threatening diseases including cancer and AIDS



Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com

]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/06/june-19-2009-aurgalys-cls-initiates-analyst-coverage-of-bioalliance-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jan 06, 2009: Aurgalys and Cukierman &amp; Co Life Sciences sign a business affiliate agreement to offer global solutions</title>
		<link>http://www.aurgalys.com/2009/01/aurgalys-and-cukierman-co-life-sciences-sign-a-business-affiliate-agreement-to-offer-global-solutions/</link>
		<comments>http://www.aurgalys.com/2009/01/aurgalys-and-cukierman-co-life-sciences-sign-a-business-affiliate-agreement-to-offer-global-solutions/#comments</comments>
		<pubDate>Mon, 05 Jan 2009 23:00:58 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=522</guid>
		<description><![CDATA[
January 6th, 2009, Aurgalys and Cukierman &#38; Co Life Sciences sign a business affiliate agreement to offer global solutions to the life science industry in Europe, North America and Israel
Given the current global financial crisis and new market needs, the partners&#8217; core service offering focuses on M&#38;A activity and strategic alliances
Download our English Press Release [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/01/aurgalys-and-cukierman-co-life-sciences-sign-a-business-affiliate-agreement-to-offer-global-solutions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
